News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
Content Sharing
<Research>M Stanley: BUD APAC (01876.HK) Quarterly Results Weak, in Line; Rating Kept at Overweight
BUD APAC (01876.HK) announced that its 4Q25 revenue was US$1.073 billion (organic revenue down 4.2% YoY), compared to the market consensus of US$1.08 billion and Morgan Stanley'...
Reset
Send
The window will close in 5 seconds
<Research>M Stanley: BUD APAC (01876.HK) Quarterly Results Weak, in Line; Rating Kept at Overweight
Close
Recommend
4
Positive
6
Negative
5
 
 

BUD APAC (01876.HK)  +0.210 (+2.861%)    Short selling $41.49M; Ratio 190.657%   announced that its 4Q25 revenue was US$1.073 billion (organic revenue down 4.2% YoY), compared to the market consensus of US$1.08 billion and Morgan Stanley's expectation of US$1.07 billion, according to Morgan Stanley's research report.

Adjusted EBITDA was US$167 million (organic revenue down 24.7% YoY), below the expectations of the market/ broker of US$183 million/ US$202 million. Adjusted net loss amounted to US$12 million.

During the period, the Group's sales in the China market fell by 11.4%, and volume decreased by 3.9% (decline narrowed, with stabilized market share), with the organic average selling price down 7.7% YoY, mainly due to higher investment in trade channels and in-home/emerging channels.

Therefore, the broker rated BUD APAC at Overweight, with a target price of $9.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-02 16:25.)

AASTOCKS Financial News

Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.